Peak Pharmaceuticals, Inc. (CIK 0001452804, trading as PKPH, now associated with RMHI per metadata) is a self-described shell company with no operations, no revenue, and no tangible productive assets. As of December 31, 2022, total assets consist entirely of cash ($96,720) and prepaid expenses ($5,760), summing to $102,480. Under the liquidation lens, cash recovers at 100% ($96,720) and prepaid expenses recover at approximately zero (no realizable value in wind-down), yielding a liquidation asset pool of roughly $97,000. Against this stands total liabilities of $705,876, all classified as current: accounts payable $307,146 (of which $199,693 is owed to related parties), accrued liabilities $125,730, convertible notes payable $10,000 (the Trius Holdings note, matured March 2019, currently accruing at default 15%), and notes payable $228,000 plus notes payable to a related party $35,000. All notes are unsecured and in default; maturity extensions have not been obtained. Under the liquidation lens, all liabilities remain at face value. Liquidation recovery to equity is therefore approximately negative $609,000 ($97,000 assets minus $705,876 liabilities), consistent with the reported stockholders' deficit of ($603,396). Compared to the prior filing period (September 30, 2022), the deficit widened from ($491,154) to ($603,396), a deterioration of approximately $112,000 in one quarter, driven entirely by the net operating loss of $112,242. The primary driver of operating losses is G&A expense, which jumped to $110,412 in Q1 FY2023 versus $52,063 in Q1 FY2022, largely attributable to increased accounting fees including $46,012 billed by an entity controlled by the sole officer and director. Cash burned $30,879 in the quarter (operating only; no financing activity), leaving $96,720 at period end versus $127,599 at September 30, 2022. At the current burn rate, the company has less than three quarters of operating runway on existing cash before insolvency on a cash basis, with no revenue source. A subsequent event (January 23, 2023 Settlement Agreement) resulted in approximately $45,490 gain on forgiveness of accounts payable, including $24,340 from related parties; this was not reflected on the December 31, 2022 balance sheet. The filing explicitly discloses going concern doubt. No intangibles, PP&E, inventory, or long-term assets exist. The XBRL tag context provided is empty; therefore no individual tags are flagged below, and all quantitative references derive from inline XBRL values parsed from the filing body.
▼ Community Notes